https://edgen.pre.edgen.tech/news/post/vesta-to-offer-70-million-shares-in-global-follow-on-deal2026-05-07T11:49:51.733Zdaily1Edgen Stocken2026-05-07T11:49:51.733+00:00Vesta to Offer 70 Million Shares in Global Follow-On Dealhttps://static.edgen.tech/news/images/vesta-to-offer-70-million-shares-in-global-follow-on-deal-20260507.pngVesta to Offer 70 Million Shares in Global Follow-On Deal https://edgen.pre.edgen.tech/news/post/himax-projects-up-to-13-revenue-growth-on-auto-and-ai-strength2026-05-07T11:48:51.885Zdaily1Edgen Stocken2026-05-07T11:48:51.885+00:00Himax projects up to 13% revenue growth on auto and AI strengthhttps://static.edgen.tech/news/images/himax-projects-up-to-13-revenue-growth-on-auto-and-ai-strength-20260507.pngHimax projects up to 13% revenue growth on auto and AI strength https://edgen.pre.edgen.tech/news/post/cheniere-energy-swings-to-q1-loss-on-gas-derivatives2026-05-07T11:48:49.908Zdaily1Edgen Stocken2026-05-07T11:48:49.908+00:00Cheniere Energy Swings to Q1 Loss on Gas Derivativeshttps://static.edgen.tech/news/images/cheniere-energy-swings-to-q1-loss-on-gas-derivatives-20260507.pngCheniere Energy Swings to Q1 Loss on Gas Derivatives https://edgen.pre.edgen.tech/news/post/knight-therapeutics-raises-2026-revenue-forecast-after-record-q1-results2026-05-07T11:47:33.487Zdaily1Edgen Stocken2026-05-07T11:47:33.487+00:00Knight Therapeutics raises 2026 revenue forecast after record Q1 resultshttps://static.edgen.tech/news/images/knight-therapeutics-raises-2026-revenue-forecast-after-record-q1-results-20260507.pngKnight Therapeutics raises 2026 revenue forecast after record Q1 results https://edgen.pre.edgen.tech/news/post/nuvalent-gets-september-18-pdufa-date-for-zidesamtinib-in-lung-cancer2026-05-07T11:46:11.665Zdaily1Edgen Stocken2026-05-07T11:46:11.665+00:00Nuvalent gets September 18 PDUFA date for zidesamtinib in lung cancerhttps://static.edgen.tech/news/images/nuvalent-gets-september-18-pdufa-date-for-zidesamtinib-in-lung-cancer-20260507.pngNuvalent gets September 18 PDUFA date for zidesamtinib in lung cancer https://edgen.pre.edgen.tech/news/post/trilogy-metals-gains-as-14-million-acre-transfer-aids-ambler-road2026-05-07T11:43:39.486Zdaily1Edgen Stocken2026-05-07T11:43:39.486+00:00Trilogy Metals Gains as 1.4 Million Acre Transfer Aids Ambler Roadhttps://static.edgen.tech/news/images/trilogy-metals-gains-as-14-million-acre-transfer-aids-ambler-road-20260507.pngTrilogy Metals Gains as 1.4 Million Acre Transfer Aids Ambler Road https://edgen.pre.edgen.tech/news/post/united-labs-class-1-drug-ubt38006-gets-china-trial-approval2026-05-07T11:40:24.467Zdaily1Edgen Stocken2026-05-07T11:40:24.467+00:00United Lab's class 1 drug UBT38006 gets China trial approvalhttps://static.edgen.tech/news/images/united-labs-class-1-drug-ubt38006-gets-china-trial-approval-20260507.pngUnited Lab's class 1 drug UBT38006 gets China trial approval https://edgen.pre.edgen.tech/news/post/rsun-ppt-april-contracted-sales-plunge-64-amid-china-property-woes2026-05-07T11:39:46.870Zdaily1Edgen Stocken2026-05-07T11:39:46.870+00:00Rsun Ppt April Contracted Sales Plunge 64% Amid China Property Woeshttps://static.edgen.tech/news/images/rsun-ppt-april-contracted-sales-plunge-64-amid-china-property-woes-20260507.pngRsun Ppt April Contracted Sales Plunge 64% Amid China Property Woes https://edgen.pre.edgen.tech/news/post/hkbn-invests-hkd-100-million-in-ai-platform-with-chinese-gpus2026-05-07T11:37:45.316Zdaily1Edgen Stocken2026-05-07T11:37:45.316+00:00HKBN invests HKD 100 million in AI platform with Chinese GPUshttps://static.edgen.tech/news/images/hkbn-invests-hkd-100-million-in-ai-platform-with-chinese-gpus-20260507.pngHKBN invests HKD 100 million in AI platform with Chinese GPUs https://edgen.pre.edgen.tech/news/post/tennor-therapeutics-gets-green-light-for-hong-kong-ipo-under-chapter-18a2026-05-07T11:36:49.266Zdaily1Edgen Stocken2026-05-07T11:36:49.266+00:00TenNor Therapeutics gets green light for Hong Kong IPO under Chapter 18Ahttps://static.edgen.tech/news/images/tennor-therapeutics-gets-green-light-for-hong-kong-ipo-under-chapter-18a-20260507.pngTenNor Therapeutics gets green light for Hong Kong IPO under Chapter 18A https://edgen.pre.edgen.tech/news/post/us-shale-output-climbs-as-oil-prices-top-100-on-war-disruption2026-05-07T11:35:15.210Zdaily1Edgen Stocken2026-05-07T11:35:15.210+00:00US shale output climbs as oil prices top $100 on war disruptionhttps://static.edgen.tech/news/images/us-shale-output-climbs-as-oil-prices-top-100-on-war-disruption-20260507.pngUS shale output climbs as oil prices top $100 on war disruption https://edgen.pre.edgen.tech/news/post/shell-stock-drops-despite-profit-beat-as-trading-windfall-questioned2026-05-07T11:35:13.504Zdaily1Edgen Stocken2026-05-07T11:35:13.504+00:00Shell Stock Drops Despite Profit Beat as Trading Windfall Questionedhttps://static.edgen.tech/news/images/shell-stock-drops-despite-profit-beat-as-trading-windfall-questioned-20260507.pngShell Stock Drops Despite Profit Beat as Trading Windfall Questioned https://edgen.pre.edgen.tech/news/post/s4-capital-falls-13-after-q1-net-revenue-declines-52026-05-07T11:34:40.471Zdaily1Edgen Stocken2026-05-07T11:34:40.471+00:00S4 Capital Falls 13% After Q1 Net Revenue Declines 5%https://static.edgen.tech/news/images/s4-capital-falls-13-after-q1-net-revenue-declines-5-20260507.pngS4 Capital Falls 13% After Q1 Net Revenue Declines 5% https://edgen.pre.edgen.tech/news/post/us-shale-firms-add-just-30000-barrels-despite-42-price-surge2026-05-07T11:33:10.521Zdaily1Edgen Stocken2026-05-07T11:33:10.521+00:00US shale firms add just 30,000 barrels despite 42% price surgehttps://static.edgen.tech/news/images/us-shale-firms-add-just-30000-barrels-despite-42-price-surge-20260507.pngUS shale firms add just 30,000 barrels despite 42% price surge https://edgen.pre.edgen.tech/news/post/yzybio-bs-m701-drug-application-for-ascites-accepted-in-china2026-05-07T11:29:29.862Zdaily1Edgen Stocken2026-05-07T11:29:29.862+00:00YZYBIO-B's M701 drug application for ascites accepted in Chinahttps://static.edgen.tech/news/images/yzybio-bs-m701-drug-application-for-ascites-accepted-in-china-20260507.pngYZYBIO-B's M701 drug application for ascites accepted in China https://edgen.pre.edgen.tech/news/post/eu-weighs-restricting-us-clouds-for-government-data-impacting-billions2026-05-07T11:27:13.315Zdaily1Edgen Stocken2026-05-07T11:27:13.315+00:00EU Weighs Restricting US Clouds for Government Data, Impacting Billionshttps://static.edgen.tech/news/images/eu-weighs-restricting-us-clouds-for-government-data-impacting-billions-20260507.pngEU Weighs Restricting US Clouds for Government Data, Impacting Billions https://edgen.pre.edgen.tech/news/post/a-24-year-olds-fund-bets-9-billion-on-ais-energy-needs2026-05-07T11:21:31.767Zdaily1Edgen Stocken2026-05-07T11:21:31.767+00:00A 24-year-old's fund bets $9 billion on AI's energy needshttps://static.edgen.tech/news/images/a-24-year-olds-fund-bets-9-billion-on-ais-energy-needs-20260507.pngA 24-year-old's fund bets $9 billion on AI's energy needs https://edgen.pre.edgen.tech/news/post/cognyte-software-jumps-7-on-strong-2027-outlook-20m-contract2026-05-07T11:19:59.987Zdaily1Edgen Stocken2026-05-07T11:19:59.987+00:00Cognyte Software Jumps 7% on Strong 2027 Outlook, $20M Contracthttps://static.edgen.tech/news/images/cognyte-software-jumps-7-on-strong-2027-outlook-20m-contract-20260507.pngCognyte Software Jumps 7% on Strong 2027 Outlook, $20M Contract https://edgen.pre.edgen.tech/news/post/sjm-holdings-swings-to-a-hk62-million-q1-loss-on-softer-gaming-revenue2026-05-07T11:19:47.681Zdaily1Edgen Stocken2026-05-07T11:19:47.681+00:00SJM Holdings Swings to a HK$62 Million Q1 Loss on Softer Gaming Revenuehttps://static.edgen.tech/news/images/sjm-holdings-swings-to-a-hk62-million-q1-loss-on-softer-gaming-revenue-20260507.pngSJM Holdings Swings to a HK$62 Million Q1 Loss on Softer Gaming Revenue https://edgen.pre.edgen.tech/news/post/danuo-pharma-passes-hkex-hearing-for-ipo-with-7-program-pipeline2026-05-07T11:16:53.693Zdaily1Edgen Stocken2026-05-07T11:16:53.693+00:00Danuo Pharma passes HKEX hearing for IPO with 7-program pipelinehttps://static.edgen.tech/news/images/danuo-pharma-passes-hkex-hearing-for-ipo-with-7-program-pipeline-20260507.pngDanuo Pharma passes HKEX hearing for IPO with 7-program pipeline